How much is Affinivax worth in 2026?

Affinivax has a current valuation of N/A based on their Later Stage VC (Series C) round and secondary market data.

How much funding has Affinivax raised?

Affinivax has raised N/A in total funding across 2 funding rounds.

Affinivax

Drug Discovery

Affinivax valuation and funding history | Last updated: May 3, 2021 | 2 funding rounds

Current Valuation

N/A

As of May 3, 2021

Total Funding Raised

N/A

Across 2 rounds

Last Round

Later Stage VC (Series C)

$226.0M

Last Funding

May 2021

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
May 3, 2021	Later Stage VC (Series C)	$226.0M	N/A	-
April 23, 2020	Later Stage VC (Series B)	$120.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Affinivax is currently valued at N/A as of May 3, 2021.

Track Affinivax Valuation Updates

Get notified when Affinivax raises new funding or valuation changes

Explore More Data

Detailed analysis for Affinivax

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Affinivax's valuation history, funding rounds, and growth metrics.

No credit card required

What is Affinivax Worth in 2026?

Affinivax is a leading private company in the Drug Discovery sector. Track Affinivax's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Affinivax Valuation is Determined

Private company valuations like Affinivax's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.